Close Menu

NEW YORK — Quotient Limited said on Friday that it has received CE marking for its SARS-CoV-2 antibody microarray test.

The MosaiQ COVID-19 Antibody Microarray is designed to detect human immunoglobulin G and M antibodies against SARS-CoV-2. It runs on the company's CE-marked Mosaiq automated testing system.

Quotient, headquartered in Eysins, Switzerland, said the assay has demonstrated 100 sensitivity and 99.8 percent specificity and was able to detect antibodies early in seroconversion in clinical testing.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

Sponsored by
Thermo Fisher Scientific

Global genetic surveillance is vital for understanding the evolution of viral pathogens and monitoring for changes in transmissibility, virulence, disease pathology, and impact on the efficacy of diagnostic tests, therapeutics, and vaccines.

Sponsored by
Beckman Coulter

In this webinar session, Dr. David Harris and Dr. Ryan Sprissler, who led the student and employee testing program at University of Arizona, will discuss how the university has remained physically open with nearly 25 percent of its population on campus, while keeping infection rates below 2 percent.